Drug-Drug Interaction Study to Evaluate the Pharmacokinetics and Safety of CTX 4430 and Midazolam
Status:
Completed
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
This drug-drug interaction study will assess the potential of CTX-4430 to induce CYP3A
activity in healthy subjects.
The study hypothesis is that midazolam (a sensitive, widely used CYP3A4 substrate) blood
levels will not change after treatment with CTX-4430.